ENXTPA:SANPharmaceuticals
Sanofi’s Rare Disease And CAR T Advances Versus Current Valuation Picture
Sanofi received FDA Breakthrough Therapy designation for venglustat in type 3 Gaucher disease.
The designation focuses on neurological manifestations of Gaucher disease type 3.
Sanofi presented preclinical data for an mRNA based in vivo CAR T platform designed for transient CAR expression.
For investors tracking ENXTPA:SAN, these updates add fresh angles to the story beyond recent attention on Dupixent and acoziborole. The shares last closed at €76.89, and longer term returns show mixed...